MINTEZOL
LOE ApproachingNDAORALSUSPENSION
Approved
Apr 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MINTEZOL is an oral suspension approved in 1967 by Merck & Co. for parasitic infections. The drug's specific mechanism of action and indications are not detailed in available data, but its longevity suggests broad antiparasitic utility. As a legacy small-molecule product, it remains a foundational therapy in its indication class.
LOE Approaching
Product is nearing loss of exclusivity with minimal current linked job activity, suggesting a contracted team focused on maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MINTEZOL at this lifecycle stage offers limited growth but valuable experience in managing LOE transitions, generic competition response, and portfolio optimization. Career advancement is constrained; opportunities lie in mastering cost management and competitive defense strategies.
Brand ManagerCommercial Operations Manager
Worked on MINTEZOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.